



MaaT Pharma Announces Initiation of Coverage of its Stock by KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas

Lyon, France, January 13, 2022 – 7:00pm CET – [MaaT Pharma](#) (EURONEXT: MAAT - the “Company”), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, announces the initiation of coverage of its stock by KBC Securities, Kempen and Portzamparc / Groupe BNP Paribas.

With a research report named “*Échec et MaaT pour le cancer*”, [Portzamparc / Groupe BNP Paribas](#) today initiates coverage of MaaT Pharma with a Buy recommendation.

This coverage of MaaT Pharma stock comes in addition to the ones initiated in December 2021 by brokerage firms [KBC Securities](#) with a Buy recommendation (research report “*More than a Gut Feeling*”) and [Kempen](#), also with a Buy recommendation (research report “*No Guts no Glory*”).

Next financial communication:

- **February 28th, 2022, after stock market closes:** publication of the 2021 revenues and cash position as of December 31st, 2021.

About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in a Phase II clinical trial in acute GvHD. Our powerful discovery and analysis platform, gutPrint®, supports the development and expansion of our pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions.

The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.

MaaT Pharma is listed on Euronext Paris (ticker: MAAT).



Contacts

MaaT Pharma
Hervé AFFAGARD
Co-Founder and CEO
Siân Crouzet, COO/ CFO
+33 4 28 29 14 00
invest@maat-pharma.com

MaaT Pharma
Pauline RICHAUD
Senior PR & Corporate
Communications Manager
+33 6 07 55 25 36
prichaud@maat-pharma.com

Trophic Communications
Corporate Communications
Jacob VERGHESE or
Gretchen SCHWEITZER
+49 89 23 88 77 31
maat@trophic.eu